• Article highlight
  • Article tables
  • Article images

Article History

Received : 10-04-2021

Accepted : 13-04-2021



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 1210

PDF Downloaded: 643


Get Permission Khanam and Vayaravel: Medicinal plants effective against Alzheimer’s disease: An update


Introduction

The word ‘herb’ refers to each and every part of the plant. The use of plants for medicinal purposes dates back to as early as 4000 years ago. Due to their minimal side effects, treatment with medicinal plants is considered safe. The contribution of plant drugs is as high as 80% from India and China. Medicinal herbs are now essential sources for pharmaceutical production. More than 75% of the global population depends mainly on plants/plant extracts for their health care needs.1 With the introduction of AYUSH (Department of Ayurveda, Yoga, and Naturopathy, Unani, Siddha, and Homeopathy) as early as 2003, not only equal importance was given to the natural way of treating various diseases but also the research and development was geared up in the above fields. One of the main objectives is to improve the current research institutions and to ensure a time-bound research program on diseases. In India's AYUSH programs, over 8,000 herbal remedies have been codified.2 Out of the several diseases targeted by these medicinal herbs, we are concentrating this review on Alzheimer’s disease.

Chronic neurodegeneration leading to Alzheimer's disease (AD) has become a major health challenge affecting over 50 million people globally with a prediction to reach 152 million by 2050.3 Multiple factors are responsible for neuronal damage including oxidative stress and accumulation of the amyloid β (Aβ) protein in the brain. However, the biggest challenge here is in its treatment. Currently, the two classes of drugs approved to treat AD, include inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA). These regimens are mainly targeted towards alleviating the symptoms and palliative effects only; not in preventing the neurodegeneration or initiating neuronal repairing.4, 5, 6 Thus, the urge for novel research for treating this disease is imperative. And here comes the medicinal plants which are the important leads for drug development against AD. Though their mechanism of action is yet to be elucidated, phytochemical studies have revealed that they have a wide spectrum of pharmacological activities like antioxidants, anti-inflammatory, anti-cholinesterase, anti-amyloidogenic and hypolipidemic effects.7 Traditionally, several herbal preparations are used to enhance the cognitive activity of the elderly. Researchers have turned to phytotherapy due to a lack of new treatment approaches and strategies for AD.8 Several clinical and in vivo experiments have been performed to assess the magnitude and true potentials of certain medicinal plants that are thought to enhance memory, identify biologically active constituents, and reveal the underlying pathways. This study will focus on the most current scientific results on the potential of a variety of medicinal plants in the treatment of AD.

Alzheimer’s disease

Alzheimer's disease (AD) is a neurodegenerative disease that mostly affects the elderly. Alois Alzheimer, a German neuropathologist and psychiatrist, discovered AD in 1906. AD is characterized by memory loss, decreased speech function, performance impairment, disorientation, behavior deterioration, gait irregularities, and thought slowness. 9 Extreme depression is a condition that resembles the condition. The accumulation of oxidative damage to nucleic acid, protein, and mitochondria in the brain causes cognitive and neurological impairment. Patients aged 65 to 74 years old had a prevalence of 3.0 percent, while people aged 85 years old had a prevalence of 47.2 percent. 10 Due to duplication or mutation of β -amyloid precursor proteins (APP) and a presenilin-encoding gene for proteolytic enzymes, AD is characterized by elevated neurofibrillary tangles and β-amyloid levels. Brain neurodegeneration and β-amyloid (Aβ) deposition are used as biomarkers to identify people at risk of AD. Neurodegenerative diseases are caused by a combination of environmental and genetic causes, as well as aging. AD begins with changes in normal brain functions, first with an inability to produce new memory due to the difficulties of consolidating new memory, which contributes to rapid forgetting. 11 Plaques develop, which are then accompanied by inflammation, a loss of cholinergic function, and stress. Some changes in the microglia induce inflammation in the central nervous system (CNS), which raises the risk of neurological aging and AD. Antioxidant enzymes normally counteract oxidative stress in a natural physiological state, but in AD, these enzymes fail to fulfill their normal function in the brain. Pathology of AD progresses from the perirhinal zone to the hippocampus complex, then to the temporal lobes with the basal forebrain. 12 AD is predominantly concerned with emotions, and it has an impact on both patients' and caregivers' quality of life. Good or detrimental improvements in behavior are important criteria for determining the quality of life in Alzheimer's patients. Aging, genetics, education, ethnicity, and the apolipoprotein E ε4 allele, all play a role in the development of AD. 13 AD and dementia are exacerbated by cardiovascular disease, diabetes, and smoking. Current approaches focus on helping people manage behavioral symptoms, maintain mental function, and slow or delay the symptoms of the disease. Researchers hope to develop therapies targeting specific genetic, molecular, and cellular mechanisms so that the actual underlying cause of the disease can be stopped or prevented. Targeting neuritic plaques (NPs) and neurofibrillary tangles (NFTs), which have the ability to prolong neurodegeneration, is the future of AD care. 14

Causes

Two major hypotheses have been proposed as a cause of AD viz. Cholinergic & Amyloid hypothesis.

Cholinergic hypothesis

Acetylcholine (Ach) synthesized from acetyl coenzyme A and choline catalyzed by the enzyme acetylcholinesterase, in the cytoplasm of cholinergic neurons and transported to the synaptic vesicles. Ach serves vital roles in the brain like sensory information, memory, attention, and learning. Degeneration of these cholinergic neurons leads to cholinergic synaptic loss and amyloid fibril formation leading to derangement in memory and cognitive function. 15, 16

Amyloid hypothesis

A strong correlation exists between dementia and the deposition of amyloid β (Aβ) protein in the central nervous system. The degradation of this protein by the enzyme secretase is diminished either by age or pathologically leading to the formation of amyloid fibrils which leads to neuronal cell death and neurodegeneration. 17, 18, 19

Pathogenesis

Patients with AD have two distinct characteristics in their brains.

  1. Extracellular deposits of amyloid-beta (Aβ), a peptide formed by the breakdown of Aβ precursors (genetic locus 21q21–22), can be found in senile plaques. Abnormal deposit of Aβ has also been found in blood vessels. 20

  2. People with AD have neurofibrillary tangles, which are thick clusters of irregular fibers in the cytoplasm of neurons made up of an altered version of the microtubular-associated protein. 21

Stages of AD

  1. Pre-symptomatic: mild memory loss with no functional impairment of routine activities

  2. Early: the appearance of several symptoms with loss of concentration and memory.

  3. Moderate: increased memory loss and difficulty in reading, speaking, writing, and recognizing the family members, with the disease spreading in the cerebral cortex

  4. Severe: complete cognitive impairment due to accumulation of neuritic plaques proving fatal 22, 23, 24, 25.

Risk Factors

A recent review has identified more than 50 environmental risk factors.26 Armstrong RA in his review has grouped the various risk factors under broad categories as in the tabular column below.27

Table 0

S. No.

Grouping

Risk factors

01

Demographic

Age, Education, Gender Race, Social class

02

Genetics

Amyloid precursor protein (APP), Presenilin 1 and 2 (PSEN1/2), Apolipoprotein E (APOE), ATP-binding cassette transporter A1, (ABCA1), Adaptor protein evolutionarily conserved signaling intermediate in Toll pathway (ECSIT), Clusterin gene (CLU), Estrogen receptor gene (ESR), Fermitin family homolog 2 gene (FERMT2), Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Histocompatibility locus antigen (HLA class III), mtDNA haplotype Transferrin gene (Tf), Triggering receptor expressed on myeloid cells 2 (TREM 2), Vascular protein sorting-10 domain (VpS10) genes, Vitamin D receptor gene (VDR), Epigenetic factors

03

Lifestyle

Alcohol, Lack of exercise, Lack of cognitive activity, Malnutrition, Poor diet, Smoking

04

Medical

Cancer, Cardiovascular disease, Congestive heart failure, Immune system dysfunction, Micro-infarcts, Obesity, Poor cholesterol homeostasis, Poorly controlled type-2 diabetes, Stroke, Traumatic brain injury

05

Psychiatric

Depression, Early stress

06

Environmental

Air pollution, Calcium deficiency, Geographic location, Metals (especially aluminium, copper, zinc), Military service, Organic solvents, Occupation, Vitamin deficiency

07

Infections

Bacteria, e.g. Chlamydophila pneumonia, Treponema, Dental infections, Fungi, Viruses

The genetic and environmental factors increase the release of oxygen free radicals thereby aggravating normal aging. 28

Diagnosis

It is important to get an early and correct diagnosis of AD so that treatment can begin as soon as possible. To increase the chances of living a normal and stable life, these herbal therapies should begin as soon as possible after diagnosis (along with daily brain exercises). 29

A Comprehensive analysis that contains the following examinations will correctly detect AD: 30

  1. A detailed medical and mental history is needed

  2. A neurological examination

  3. Anemia, vitamin deficiency, and other disorders may all be ruled out of laboratory testing

  4. A mental status assessment is used to assess a person's ability to think and remember

  5. Having a conversation with family members or caregivers

Herbal Treatment

In recent years, interest in herbal medicine has grown, resulting in expanded research interest in the therapeutic use of plants to cure illness and improve health, often without causing major side effects. Herbal medications and herbal ingredients are among the world's oldest treatments. Medicinal plants have been used by all cultures throughout history. In the current situation, the market for herbal products is increasing exponentially all over the world. 6

Herbs with anti-inflammatory and antioxidant properties can be useful in the treatment of AD. Acetylcholine deficiency is common in Alzheimer's patients. German chamomile, licorice, turmeric, and white willow bark are anti-inflammatory herbs that can help to reduce inflammation of the brain tissue in AD. Acetylcholine is a neurotransmitter that is essential for cognitive function and reasoning. Mild-to-moderate AD, a chronic form of dementia, has abnormally low acetylcholine concentrations in the brain. This suggests that any substance that improves the cholinergic pathway in the brain may be beneficial in the treatment of AD and other brain disorders. The herbs that inhibit Acetylcholinesterase (AchE) contain natural COX-2 inhibitors, also reported as medicinal herbs, for AD indication. 31

Due to the lack of a sufficient number of treatment options, the management of AD has remained a major concern for medical research over the years; only a few drugs have been developed and accepted by the US FDA as of today. Natural ingredients may be the ideal choice for producing an anti-AD drug due to their diversity of structures and functions. Secondary metabolites derived from medicinal plants have the ability to be converted into a lead molecule effective against AD, according to research. Various medicinal plants have been recapitulated in tabular form (Table 1) in this review based on their therapeutic potential to treat AD.

Table 1

Medicinal plants used for the treatment of Alzheimer’s disease

S. No.

Medicinal plants (Family)

Parts of the plant used

Bioactive constituents

Properties

Ref

01

Curcuma longa (Zingiberaceae)

Rhizome extracts

Curcumins, flavonoids, phenols

Neuroprotective, anti-inflammatory, protein hyperphosphorylation inhibitor

32

02

Ginkgo biloba (Ginkgoaceae)

Leaf extracts

Antioxidant, AChE inhibitor

Terpenes, bilobalide, ginkgolide

33

03

Bacopa monniera (Plantaginaceae)

Leaf extracts

Brahmine, herpestine

Antioxidant, antilipoxygenase

34

04

Withania somnifera (Solanaceae)

Root extracts

Sitoindosides, withaferin

Antioxidant, adaptogenic, leukotriene signaling inhibitor

35

05

Panax ginseng (Araliaceae)

Root extracts

Ginsenosides, gintonin

Neuroprotective

36, 37

06

Sargassum sagamianum (Sargassaceae)

Seaweed extracts

Plastoquinon, sargachrome, sargaquinoic acid

AChE inhibitor

38

07

Crocus sativus (Iridaceae)

Dry stigma powder

Crocin, crocetin, picrocrocin, and safranin

Antioxidant, neuroprotective

39

08

Convolvulus pluricaulis (Convolvulaceae)

Leaf extracts

Ascorbic acid, flavonoids, rivastigmine, terpenoids, steroids

Antioxidant, muscarinic receptor stabilizer

40

09

Ficus carica (Moraceae)

Mesocarp extract

C-Sitosterol

Antioxidant

41

10

Psidium guajava (Myrtaceae)

Leaf and fruit extract

Linoleic acid

Antioxidant, antidiabetic

42

11

Lawsonia inermis (Lythraceae)

Leaf extract

Phytol, pseudoephedrine, aspidofractinine-3-methanol, phenol, 2,6-bis (1,1-dimethyl ethyl)-4-methyl, methylcarbamate

Antioxidant, nootropic potential

43

12

Clitoria ternatea (Fabaceae)

Leaf and root extracts

Quercetin and myricetin glycosides

Brain tonic antioxidant, muscarinic receptor stabilizer

44

13

Lavandula angustifolia (Lamiaceae)

Arial part extract

Linalool, tannins, linalyl acetate, camphor, coumarins, triterpenes, flavonoids

Antioxidant, neurotransmitter, antianxiety, hypnotic, anticonvulsant

45

14

Coriandrum sativum (Apiaceae)

Leaf extract, volatile oil

Petroselinic acid, linalool, fatty acids

Antioxidant, antidepressant, and anxiolytic

46

15

Mangifera indica (Anacardiaceae)

Leaf extract

Flavonoids, phenols

Antipyretic, antioxidant

47

16

Ferula asafetida (Apiaceae)

Whole plant extract, resins

Ferulic acid, umbelliferone, coumarins, and other terpenoids

AChE inhibitor, antioxidant activity

48

17

Saururus chinensis (Saururaceae)

Whole plant extract

Flavonoids, alkaloids, α-pinene, cinnamic acid, camphene, safrole, β-caryophyllene, linalool, and humulene

Antioxidant, anti-inflammatory

49

18

Syagrus romanzoffiana (Arecaceae)

Leaf and fruit extract

Stilbenoids, flavonoids, lignans, phenols, and fatty acids

AChE inhibitor

50

19

Hancornia speciosa (Apocynaceae)

Fruit extracts

Flavonoids, phenols, tannins

Antioxidant, AChE inhibitor

51

20

Andrographis paniculata (Acanthaceae)

Active compound

Grandifloric acid, phenolic acids

AChE, BChE, and BACE-1 inhibitor

52

Conclusion

AD is the most common neurodegenerative disease in the world, and there are no effective medications or therapies to cure it. It encourages the discovery of new chemical entities, with medicinal plants playing a vital role as a rich source of pharmacological principles and variability. Herbs may play a promising role in the early management of AD and other conditions involving poor memory and dementia. One of the chief benefits is that they have low toxicity compared to pharmaceutical agents. The secondary metabolites of plants with flavonoids, alkaloids, and phenolic acids play a crucial role in improving regeneration and/or inhibiting neurodegeneration. These drugs may help to enhance memory in patients. Thus, the knowledge of medicinal plants helps to develop drugs in the modern medicine system.

Conflicts of Interest

All contributing authors declare no conflicts of interest.

Source of Funding

None.

References

1 

www.nhp.gov.in

2 

www.ayush.gov.in

3 

Z Breijyeh R Karaman Comprehensive Review on Alzheimer’s Disease: Causes and TreatmentMolecules20202524578910.3390/molecules25245789

4 

KG Yiannopoulou SG Papageorgiou Current and Future Treatments in Alzheimer Disease: An UpdateJ Cent Nerv Syst Dis20201211795735209073910.1177/1179573520907397

5 

G Livingston J Huntley A Sommerlad D Ames C Ballard S Banerjee Dementia prevention, intervention, and care: 2020 report of the Lancet CommissionLancet2020396102484134610.1016/s0140-6736(20)30367-6

6 

Muhammad Akram Allah Nawaz Effects of medicinal plants on Alzheimer's disease and memory deficitsNeural Regeneration Research20171246606601673-537410.4103/1673-5374.205108Medknowhttps://dx.doi.org/10.4103/1673-5374.205108

7 

R V Rao O Descamps V John D E Bredesen Ayurvedic medicinal plants for Alzheimer's disease: a review20124319

8 

J Mehla P Gupta M Pahuja D Diwan D Diksha Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific AssessmentBrain Sci2020101296410.3390/brainsci10120964

9 

G K Pratap S Ashwini M Shantaram Alzheimer’s Disease: A Challenge in Managing with Certain Medicinal Plants - A ReviewInt J Pharm Sci Res2017812496072

10 

T. F. Wernicke F. M. Reischies Prevalence of dementia in old age: Clinical diagnoses in subjects aged 95 years and olderNeurology1994442250310.1212/wnl.44.2.250

11 

RE Tanzi L Bertram Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic PerspectiveCell200512045455510.1016/j.cell.2005.02.008

12 

Dale E. Bredesen Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependenceMol Neurodegener2009412710.1186/1750-1326-4-27

13 

J Lindsay D Laurin R Verreault Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and AgingAm J Epidemiol2002156544553

14 

A H Bazzari F H Bazzari Medicinal plants for Alzheimer’s disease: An updated reviewJ Med Plants Stud201862815

15 

R A Armstrong Risk factors for Alzheimer’s diseaseFolia Neuropathol20195787105

16 

P Anand B Singh A review on cholinesterase inhibitors for Alzheimer’s diseaseArch Pharmacal Res20133637599

17 

Giulia Paroni Paola Bisceglia Davide Seripa Understanding the Amyloid Hypothesis in Alzheimer’s DiseaseJournal of Alzheimer's Disease20196824935101387-2877, 1875-890810.3233/jad-180802IOS Presshttps://dx.doi.org/10.3233/jad-180802

18 

Fuyuki Kametani Masato Hasegawa Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's DiseaseFrontiers in Neuroscience20181225251662-453X10.3389/fnins.2018.00025Frontiers Media SAhttps://dx.doi.org/10.3389/fnins.2018.00025

19 

Roberta Ricciarelli Ernesto Fedele The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our MindCurrent Neuropharmacology20171569269351570-159X10.2174/1570159x15666170116143743Bentham Science Publishers Ltd.https://dx.doi.org/10.2174/1570159x15666170116143743

20 

James R. Bamburg George S. Bloom Cytoskeletal pathologies of Alzheimer diseaseCell Motility and the Cytoskeleton20096686356490886-1544, 1097-016910.1002/cm.20388Wileyhttps://dx.doi.org/10.1002/cm.20388

21 

K Iqbal B Alonso Adel C Chen S Chohan M Khatoon S Liu F Rah-man A. Tau pathology in Alzheimer’s disease and other taupa-thiesBiochem Biophys Acta20051739198210

22 

B Dubois H Hampel H H Feldman P Scheltens P Aisen S Andrieu H Bakardjian H Benali L Bertram K Blennow Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimer’s DementJ. Alzheimer’s Assoc201612292323

23 

A Kumar J Sidhu A Goyal Alzheimer Disease. In-Stat PearlsMolecules 2020202025Stat Pearls PublishingTreasure Island, FL, USA57895812

24 

Carina Wattmo Lennart Minthon Åsa K. Wallin Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapyAlzheimer's Research & Therapy201681771758-919310.1186/s13195-016-0174-1Springer Science and Business Media LLChttps://dx.doi.org/10.1186/s13195-016-0174-1

25 

Liana G. Apostolova Alzheimer DiseaseCONTINUUM: Lifelong Learning in Neurology2016222, Dementia4194341080-237110.1212/con.0000000000000307Ovid Technologies (Wolters Kluwer Health)https://dx.doi.org/10.1212/con.0000000000000307

26 

Lewis O. J. Killin John M. Starr Ivy J. Shiue Tom C. Russ Environmental risk factors for dementia: a systematic reviewBMC Geriatrics20161611751751471-231810.1186/s12877-016-0342-ySpringer Science and Business Media LLChttps://dx.doi.org/10.1186/s12877-016-0342-y

27 

R A Armstrong Risk factors for Alzheimer’s diseaseFolia Neuropathol201957287105

28 

A. S. Henderson The risk factors for Alzheimer's disease: a review and a hypothesisActa Psychiatrica Scandinavica19887832572750001-690X, 1600-044710.1111/j.1600-0447.1988.tb06336.xWileyhttps://dx.doi.org/10.1111/j.1600-0447.1988.tb06336.x

29 

Lewis H. Kuller Hormone Replacement Therapy and Its Potential Relationship to DementiaJournal of the American Geriatrics Society19964478788800002-861410.1111/j.1532-5415.1996.tb03753.xWileyhttps://dx.doi.org/10.1111/j.1532-5415.1996.tb03753.x

30 

AnilKumar Singhal OmPrakash Bangar Vijay Naithani Medicinal plants with a potential to treat Alzheimer and associated symptomsInternational journal of Nutrition, Pharmacology, Neurological Diseases20122284842231-073810.4103/2231-0738.95927Medknowhttps://dx.doi.org/10.4103/2231-0738.95927

31 

D Keyvan Dh J Damien V Heikki H Raimo Plants as Potential Sources for Drug Development against Alzheimer's DiseaseInt J Biomed Pharm Sci2007183104

32 

X Huang N Li Y Pu T Zhang Wang B Neuroprotective effects of ginseng phytochemicals: recent perspectivesMolecules2019241629392939

33 

J.-H. Heo S.-T. Lee K. Chu M. J. Oh H.-J. Park J.-Y. Shim M. Kim An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimers diseaseEuropean Journal of Neurology20081588658681351-5101, 1468-133110.1111/j.1468-1331.2008.02157.xWileyhttps://dx.doi.org/10.1111/j.1468-1331.2008.02157.x

34 

B W Choi G Ryu S H Park Anticholinesterase activity of plastoquinones from Sargassum sagamianum: lead compounds for Alzheimer's disease therapyPhytotherapy Research2007215423426

35 

S. Zahra Bathaie S. Zeinab Mousavi New Applications and Mechanisms of Action of Saffron and its Important IngredientsCritical Reviews in Food Science and Nutrition20105087617861040-8398, 1549-785210.1080/10408390902773003Informa UK Limitedhttps://dx.doi.org/10.1080/10408390902773003

36 

N Kaur B Sarkar I Gill Indian herbs and their therapeutic potential against Alzheimer’s disease and other neurological disorders.” Neuroprotective Effects of Phyto-chemicals in Neurological Disorders20177979

37 

Hanan Khojah RuAngelie Edrada-Ebel P43 The Isolation and Purification of Bioactive Metabolites from Ficus carica and Their Neuroprotective Effects in Alzheimer’s DiseaseBiochemical Pharmacology20171391401400006-295210.1016/j.bcp.2017.06.044Elsevier BVhttps://dx.doi.org/10.1016/j.bcp.2017.06.044

38 

H Y Chen Yen Gc Antioxidant activity and freeradical-scavenging capacity of extracts from guava (Psidiumguajava L.) leaves.” Food Chemistry2007101686694

39 

N T Mir U Saleem F Anwar Lawsonia inermis markedly improves cognitive functions in animal models and modulate oxidative stress markers in the brain” Medicina2019555192192

40 

Anna De Falco Daphne Schneider Cukierman Rachel A. Hauser-Davis Nicolás A. Rey ALZHEIMER'S DISEASE: ETIOLOGICAL HYPOTHESES AND TREATMENT PERSPECTIVESQuímica Nova201539163800100-404210.5935/0100-4042.20150152GN1 Genesis Networkhttps://dx.doi.org/10.5935/0100-4042.20150152

41 

A A Oskouie R F Yekta M R Tavirani M S Kashani Goshadrou F Lavandula angustifolia effects on rat models of Alzheimer's disease through the investigation of serum meta-bolic features using NMR metabolomicsAvicenna Journal of Medical Biotechnology20181028392

42 

Oana Cioanca Lucian Hritcu Marius Mihasan Adriana Trifan Monica Hancianu Inhalation of coriander volatile oil increased anxiolytic–antidepressant-like behaviors and decreased oxidative status in beta-amyloid (1–42) rat model of Alzheimer's diseasePhysiology & Behavior201413168740031-938410.1016/j.physbeh.2014.04.021Elsevier BVhttps://dx.doi.org/10.1016/j.physbeh.2014.04.021

43 

Alexandre Batista Penido Selene Maia De Morais Alan Bezerra Ribeiro Daniela Ribeiro Alves Ana Livya Moreira Rodrigues Leonardo Hunaldo dos Santos Jane Eire Silva Alencar de Menezes Medicinal Plants from Northeastern Brazil against Alzheimer’s DiseaseEvidence-Based Complementary and Alternative Medicine20172017171741-427X, 1741-428810.1155/2017/1753673Hindawi Limitedhttps://dx.doi.org/10.1155/2017/1753673

44 

Augustine Amalraj Sreeraj Gopi Biological activities and medicinal properties of Asafoetida: A reviewJournal of Traditional and Complementary Medicine2017733473592225-411010.1016/j.jtcme.2016.11.004Elsevier BVhttps://dx.doi.org/10.1016/j.jtcme.2016.11.004

45 

S H Sung S H Kwon N J Cho Y C Kim Hepato-protectiveflavonol glycosides of Saururus chinensis herbsPhytotherapy Research1997117500503

46 

Seham S. El-Hawary Fify I. Fathy Amany A. Sleem Fatma A. Morsy Mai S. Khadar Mai K. Mansour Anticholinesterase activity and metabolite profiling of Syagrus romanzoffiana (Cham.) Glassman leaves and fruits via UPLC–QTOF–PDA–MSNatural Product Research2019151478-6419, 1478-642710.1080/14786419.2019.1622113Informa UK Limitedhttps://dx.doi.org/10.1080/14786419.2019.1622113

47 

Carolina Fagundes Assumpção Patrícia Bachiega Maressa Caldeira Morzelle David Lee Nelson Eliane Augusto Ndiaye Alessandro de Oliveira Rios Éllen Cristina de Souza Characterization, antioxidant potential and cytotoxic study of mangaba fruitsCiência Rural2014447129713030103-847810.1590/0103-8478cr20130855FapUNIFESP (SciELO)https://dx.doi.org/10.1590/0103-8478cr20130855

48 

Archana N Panche Sheela Chandra AD Diwan Multi-Target β-Protease Inhibitors from Andrographis paniculata: In Silico and In Vitro StudiesPlants2019872312312223-774710.3390/plants8070231MDPI AGhttps://dx.doi.org/10.3390/plants8070231

49 

Pulok K. Mukherjee Venkatesan Kumar Mainak Mal Peter J. Houghton Acetylcholinesterase inhibitors from plantsPhytomedicine20071442893000944-711310.1016/j.phymed.2007.02.002Elsevier BVhttps://dx.doi.org/10.1016/j.phymed.2007.02.002

50 

S Bhattacharjee N Banerjee S Chatterjee Role of turmeric in management of different non-communicable diseasesWorld Journal of Pharmacy and Pharmaceutical Sciences2017617671778

51 

N. Sehgal A. Gupta R. K. Valli S. D. Joshi J. T. Mills E. Hamel P. Khanna S. C. Jain S. S. Thakur V. Ravindranath Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liverProceedings of the National Academy of Sciences20121099351035150027-8424, 1091-649010.1073/pnas.1112209109Proceedings of the National Academy of Scienceshttps://dx.doi.org/10.1073/pnas.1112209109

52 

C Dwivedi K Chandrakar V Singh Indian herbalmedicines used for treatment of dementia: an overviewInternational Journal of Pharmacognos20141553571



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.